Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo

Cancer Letters

Volumn 281, Issue 1, 2009, Pages 108-116

  Hsu, Shih Chung ^a,b   Ou, Chien Chih ^c   Chuang, Tzu Chao ^d   Li, Jhy Wei ^e,f   Lee, Yi Jen ^c   Wang, Vinchi ^g,h   Liu, Jah Yao ^c   Chen, Chin Shiang ⁱ   Lin, Song Chow ^a   Kao, Ming Ching ^e,j  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b Kang Ning Junior College of Medical Care and Management   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d TAMKANG UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f Da Chien General Hospital   (Taiwan)

^g CARDINAL TIEN HOSPITAL   (Taiwan)

^h FU JEN CATHOLIC UNIVERSITY   (Taiwan)

ⁱ CHINESE CULTURE UNIVERSITY   (Taiwan)

^j CHINA MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

Anti angiogenesis; Epidermal growth factor receptor; Epidermoid carcinoma; Ganoderma tsugae; Vascular endothelial growth factor

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GANODERMA TSUGAE EXTRACT; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; PACLITAXEL; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADENOSQUAMOUS CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG MECHANISM; GANODERMA; GANODERMA TSUGAE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; DRUGS, CHINESE HERBAL; ENDOTHELIUM, VASCULAR; EPIDERMAL GROWTH FACTOR; GANODERMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHANOL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

GANODERMA TSUGAE;

EID: 67349281217     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.032     Document Type: Article

References (37)

1. Camp E.R., Summy J., Bauer T.W., Liu W., Gallick G.E., and Ellis L.M. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin. Cancer Res. 11 (2005) 397-405
2. Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., and Kerbel R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151 (1997) 1523-1530
3. Perrotte P., Matsumoto T., Inoue K., Kuniyasu H., Eve B.Y., Hicklin D.J., Radinsky R., and Dinney C.P. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5 (1999) 257-265
4. Ciardiello F., Caputo R., Bianco R., Damiano V., Fontanini G., Cuccato S., De Placido S., Bianco A.R., and Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7 (2001) 1459-1465
5. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., and Ono M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62 (2002) 2554-2560
6. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 Suppl. 16 (2002) 15-18
7. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
8. Shiao M.S. Natural products of the medicinal fungus Ganoderma lucidum: occurrence, biological activities, and pharmacological functions. Chem. Rec. 3 (2003) 172-180
9. Lin Z.B., and Zhang H.N. Anti-tumor and immunoregulatory activities of Ganoderma lucidum and it possible mechanisms. Acta Pharmacol. Sin. 25 (2004) 1387-1395
10. Zhou X., Lin J., Yin Y., Zhao J., Sun X., and Tang K. Ganodermataceae: natural products and their related pharmacological functions. Am. J. Chin. Med. 35 (2007) 559-574
11. Wang G., Zhang J., Mizuno T., Zhuang C., Ito H., Mayuzumi H., Okamoto H., and Li J. Antitumor active polysaccharides from the Chinese mushroom Songshan lingzhi, the fruiting body of Ganoderma tsugae. Biosci. Biotechnol. Biochem. 57 (1993) 894-900
12. Zhang J., Wang G., Li H., Zhuang C., Mizuno T., Ito H., Mayuzumi H., Okamoto H., and Li J. Antitumor active protein-containing glycans from the Chinese mushroom Songshan lingzhi, Ganoderma tsugae mycelium. Biosci. Biotechnol. Biochem. 58 (1994) 1202-1205
13. Mau J.L., Lin H.C., and Chen C.C. Antioxidant properties of several medicinal mushrooms. J. Agric. Food Chem. 50 (2002) 6072-6077
14. Tang W., Liu J.W., Zhao W.M., Wei D.Z., and Zhong J.J. Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci. 80 (2006) 205-211
15. Hsu S.C., Ou C.C., Li J.W., Chuang T.C., Kuo H.P., Liu J.Y., Chen C.S., Lin S.C., Su C.H., and Kao M.C. Ganoderma tsugae extracts inhibit colorectal cancer cell growth via G2/M cell cycle arrest. J. Ethnopharmacol. 120 (2008) 394-401
16. Chuang T.C., Lee Y.J., Liu J.Y., Lin Y.S., Li J.W., Wang V., Law S.L., and Kao M.C. EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs. Biochem. Biophys. Res. Commun. 307 (2003) 653-659
17. Ou C.C., Hsu S.C., Hsieh Y.H., Tsou W.L., Chuang T.C., Liu J.Y., and Kao M.C. Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis 29 (2008) 299-306
18. Klos K.S., Wyszomierski S.L., Sun M., Tan M., Zhou X., Li P., Yang W., Yin G., Hittelman W.N., and Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 66 (2006) 2028-2037
19. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52 (1973) 2745-2756
20. Chang H., Shyu K.G., Lee C.C., Tsai S.C., Wang B.W., Lee Y.H., and Lin S. GL331 inhibits HIF-1alpha expression in a lung cancer model. Biochem. Biophys. Res. Commun. 302 (2003) 95-100
21. Li J.W., Chuang T.C., Yang A.H., Hsu C.K., and Kao M.C. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan. Int. J. Oncol. 26 (2005) 933-943
22. Qiu L., Di W., Jiang Q., Scheffler E., Derby S., Yang J., Kouttab N., Wanebo H., Yan B., and Wan Y. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int. J. Oncol. 27 (2005) 1441-1448
23. Pu Y.S., Hsieh M.W., Wang C.W., Liu G.Y., Huang C.Y., Lin C.C., Guan J.Y., Lin S.R., and Hour T.C. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem. Pharmacol. 71 (2006) 751-760
24. Sawai A., Chandarlapaty S., Greulich H., Gonen M., Ye Q., Arteaga C.L., Sellers W., Rosen N., and Solit D.B. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res. 68 (2008) 589-596
25. Ciardiello F., Caputo R., Damiano V., Caputo R., Troiani T., Vitagliano D., Carlomagno F., Veneziani B.M., Fontanini G., Bianco A.R., and Tortora G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9 (2003) 1546-1556
26. Ciardiello F., Troiani T., Bianco R., Orditura M., Morgillo F., Martinelli E., Morelli M.P., Cascone T., and Tortora G. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann. Oncol. 17 Suppl. 7 (2006) 109-114
27. Wang S.Y., Hsu M.L., Hsu H.C., Tzeng C.H., Lee S.S., Shiao M.S., and Ho C.K. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int. J. Cancer 70 (1997) 699-705
28. Chen H.S., Tsai Y.F., Lin S., Lin C.C., Khoo K.H., Lin C.H., and Wong C.H. Studies on the immune-modulating and anti-tumor activities of Ganoderma lucidum (Reishi) polysaccharides. Bioorg. Med. Chem. 12 (2004) 5595-5601
29. Hsu H.Y., F Hua K., Lin C.C., Lin C.H., Hsu J., and Wong C.H. Extract of Reishi polysaccharides induces cytokine expression via TLR4-modulated protein kinase signaling pathways. J. Immunol. 173 (2004) 5989-5999
30. Lin Z.B. Cellular and molecular mechanisms of immuno-modulation by Ganoderma lucidum. J. Pharmacol. Sci. 99 (2005) 144-153
31. Cao Q.Z., and Lin Z.B. Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci. 78 (2006) 1457-1463
32. Yue G.G., Fung K.P., Tse G.M., Leung P.C., and Lau C.B. Comparative studies of various Ganoderma species and their different parts with regard to their antitumor and immunomodulating activities in vitro. J. Altern. Complement Med. 12 (2006) 777-789
33. Yue G.G., Fung K.P., Leung P.C., and Lau C.B. Comparative studies on the immunomodulatory and antitumor activities of the different parts of fruiting body of Ganoderma lucidum and Ganoderma spores. Phytother. Res. 22 (2008) 1282-1291
34. Gan K.H., Fann Y.F., Hsu S.H., Kuo K.W., and Lin C.N. Mediation of the cytotoxicity of lanostanoids and steroids of Ganoderma tsugae through apoptosis and cell cycle. J. Nat. Prod. 61 (1998) 485-487
35. Hu H., Ahn N.S., Yang X., Lee Y.S., and Kang K.S. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int. J. Cancer 102 (2002) 250-253
36. Xie J.T., Wang C.Z., Wicks S., Yin J.J., Kong J., Li J., Li Y.C., and Yuan C.S. Ganoderma lucidum extract inhibits proliferation of SW 480 human colorectal cancer cells. Exp. Oncol. 28 (2006) 25-29
37. Stanley G., Harvey K., Slivova V., Jiang J., and Sliva D. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells. Biochem. Biophys. Res. Commun. 330 (2005) 46-52